The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse An evaluation of the effectiveness of Pulmicort Respules (budesonide inhalation suspension) versus Singulairâ (montelukast sodium) in children 2 to 8 years old with asthma requiring controller therapy.
- collapse A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5 mcg, compared with two inhalations of Seretide 25/250 mcg, two inhalations of Ventoline 100 mcg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).
- collapse A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy & Safety Study of SYMBICORT pMDI 2 x 160/4.5 mcg & 80/4.5 mcg bid Compared to Formoterol TBH, Budesonide pMDI (& the combination) & placebo in COPD Patients.
- collapse A 12-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy & Safety Study of SYMBICORT pMDI 2 x 160/4.5 mcg bid and 2 x 80/4.5 mcg bid Compared to Formoterol TBH 2 x 4.5 mcg bid and Placebo in Patients with COPD
- collapse A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations Symbicort (budesonide/formoterol) HFA pMDI 40/2.25 µg twice daily, with and without spacer, in children (6-11 years) with asthma
- collapse A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort (budesonide/formoterol) pMDI 40/2.25 µg twice daily compared with 1 inhalation Symbicort Turbuhaler 80/4.5 µg twice daily and 1 inhalation Pulmicort (budesonide) Turbuhaler 100 µg twice daily in adult and adolescent asthmatics
- collapse A Two-Week, Randomized, Double-Blind Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Pre-dose Versus Post-dose in Adult Subjects (=18 Years of Age) with Mild to Moderate Asthma, Receiving SYMBICORT pMDI 80/4.5 µg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 µg x 2 Actuations Twice Daily
- collapse A Two-Week, Randomized, Double-Blind Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects (=18 Years of Age) with Mild to Moderate Asthma, Receiving SYMBICORT pMDI 80/4.5 µg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 µg x 2 Actuations Twice Daily
- collapse A 12-week, randomized, double-blind, active-controlled, multi-center, phase IIIB study comparing the efficacy and evaluating the safety of SYMBICORT pMDI 160/4.5 µg x 2 actuations twice daily versus budesonide HFA pMDI 160 µg x 2 actuations twice daily, in adult and adolescent (=12 years) Hispanic subjects with asthma
- collapse A two-stage randomized, open-label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of SYMBICORT pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair in subjects 12 years of age and older with asthma
